Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 34, 2023 - Issue 1
Submit an article Journal homepage
878
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Certolizumab treatment of localized pyoderma gangrenosum in a pregnant patient

Na Wanga Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China;b Shandong Provincial Medical Center for Dermatovenereology, Jinan, Shandong, ChinaView further author information
,
Changping Yua Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China;b Shandong Provincial Medical Center for Dermatovenereology, Jinan, Shandong, ChinaView further author information
,
Weiwei Wanga Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China;b Shandong Provincial Medical Center for Dermatovenereology, Jinan, Shandong, ChinaView further author information
&
Qing Yanga Shandong Provincial Hospital for Skin Diseases & Shandong Provincial Institute of Dermatology and Venereology, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong, China;b Shandong Provincial Medical Center for Dermatovenereology, Jinan, Shandong, ChinaCorrespondence[email protected]
View further author information
Article: 2276044 | Received 14 Aug 2023, Accepted 16 Oct 2023, Published online: 31 Oct 2023

References

  • Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015;73(4):1–4. doi:10.1016/j.jaad.2015.06.021.
  • Alavi A, French LE, Davis MD, et al. Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2017;18(3):355–372. doi:10.1007/s40257-017-0251-7.
  • Ashchyan HJ, Nelson CA, Stephen S, et al. Neutrophilic dermatoses: pyoderma gangrenosum and other bowel- and arthritis-associated neutrophilic dermatoses. J Am Acad Dermatol. 2018;79(6):1009–1022. doi:10.1016/j.jaad.2017.11.063.
  • Patel F, Fitzmaurice S, Duong C, et al. Effectice strategies for the management of pyoderma gangrenosum: a comprehensive review. Acta Derm Venereol. 2015;95(5):525–531. doi:10.2340/00015555-2008.
  • Binus AM, Qureshi AA, Li V, et al. Pyoderma gangrenosum: a retrospective review of patients characteristics, cormorbidities and therapy in 103 patients. Br J Dermatol. 2011;165(6):1244–1250. doi:10.1111/j.1365-2133.2011.10565.x.
  • Ormerod AD, Thomas KS, Craig FE, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015;350(jun12 3):h2958–h2958. doi:10.1136/bmj.h2958.
  • Moura RR, Brandão L, Moltrasio C, et al. Different molecular pathways are disrupted in pyoderma gangrenosum patients and are associated with the severity of the disease. Sci Rep. 2023;13(1):4919. doi:10.1038/s41598-023-31914-z.
  • Ben Abdallah H, Fogh K, Vestergaard C, et al. Pyoderma gangrenosum and interleukin inhibitors: a semi-systematic review. Dermatology. 2022;238(4):785–792. doi:10.1159/000519320.
  • Ben Abdallah H, Fogh K, Bech R. Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi-systematic review. Int Wound J. 2019;16(2):511–521. doi:10.1111/iwj.13067.
  • Maronese CA, Pimentel MA, Li MM, et al. Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments. Am J Clin Dermatol. 2022;23(5):615–634. doi:10.1007/s40257-022-00699-8.
  • Romagnuolo M, Moltrasio C, Iannone C, et al. Pyoderma gangrenosum following anti-TNF therapy in chronic recurrent multifocal osteomyelitis: drug reaction or cutaneous manifestation of the disease? A critical review on the topic with an emblematic case report. Front Med. 2023;10:1197273. doi:10.3389/fmed.2023.1197273.
  • Pender TM, Ayandibu G, Van VA. Certolizumab for the treatment of localized pyoderma gangrenosum associated with Crohn’s disease: a case report. Dermatol Ther. 2020;33(6):e14352.
  • Gawdzik A, Ponikowska M, Jankowska-Konsur A, et al. Paradoxical skin reaction to certolizumab, an overlap of pyoderma gangrenosum and psoriasis in a young woman treated for ankylosing spondylitis: case report with literature review. Dermatol Ther. 2020;10(4):869–879. doi:10.1007/s13555-020-00398-4.
  • Goel N, Stephens S. Certolizumab pegol. MAbs. 2010;2(2):137–147. doi:10.4161/mabs.2.2.11271.
  • Stephens S, Brown D, Nesbitt A, et al. Lack of placental transfer and accumulation in milk of an anti-TNF PEGylated fab’ fragment in rats. J Crohn’s Colitis. 2007;1:43.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.